David Walling, PhD Quoted in Press Release Announcing FDA Approval of Alkermes’ ARISTADA INITIO™ for Schizophrenia

David Walling, PhD Quoted in Press Release Announcing FDA Approval of Alkermes’ ARISTADA INITIO™ for Schizophrenia

Alkermes plc today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA INITIO™ (aripiprazole lauroxil) for the initiation of ARISTADA® (aripiprazole lauroxil), a long-acting injectable atypical antipsychotic for the treatment of schizophrenia in adults. For the first time, ARISTADA INITIO, in combination with a single 30 mg dose of oral aripiprazole, provides physicians with an alternative regimen to initiate patients onto any dose of ARISTADA on day one.

David Walling, PhD, CEO and Principal Investigator at Collaborative Neuroscience Network, was quoted in the press release:

“The approval of ARISTADA INITIO makes ARISTADA the first and only long-acting atypical antipsychotic that can be initiated on day one, representing an important addition to the treatment paradigm for the complex illness of schizophrenia,” said Dr. Walling. “For physicians and caregivers alike, the ARISTADA INITIO regimen provides a level of confidence that patients can walk out the door with up to two months of coverage with a proven medication in their system. This supports continuity of care for patients and allows the care team to focus their efforts on other aspects of the treatment paradigm that contribute to long-term positive outcomes.”

Download the entire press release.